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Background: In view of the high risk of developing a new primary colorectal carcinoma (CRC), subtotal
colectomy rather than segmental resection or hemicolectomy is the preferred treatment in hereditary non-
polyposis colorectal cancer (HNPCC) patients. Subtotal colectomy however implies a substantial decrease
in quality of life. To date, colonoscopic surveillance has been shown to reduce CRC occurrence.
Aims: To compare the potential health effects in terms of life expectancy (LE) for patients undergoing
subtotal colectomy or hemicolectomy for CRC.
Methods: A decision analysis (Markov) model was created. Information on the 10 year risk of CRC after
subtotal colectomy (4%) and hemicolectomy (16%) and stages of CRCs detected within a two year
surveillance interval (32% Dukes’ A, 54% Dukes’ B, and 14% Dukes’ C) were derived from two cohort
studies. Five year survival rates used for the different Dukes stages (A, B, and C) were 98%, 80%, and 60%,
respectively. Remaining LE values were calculated for hypothetical cohorts with an age at CRC diagnosis of
27, 47, and 67 years, respectively. Remaining LE values were also calculated for patients with CRC of
Dukes’ stage A.
Results: The overall LE gain of subtotal colectomy compared with hemicolectomy at ages 27, 47, and 67
was 2.3, 1, and 0.3 years, respectively. Specifically for Dukes’ stage A, this would be 3.4, 1.5, and 0.4
years.
Conclusions: Unless surveillance results improve, subtotal colectomy still seems the preferred treatment for
CRC in HNPCC in view of the difference in LE. For older patients, hemicolectomy may be an option as
there is no appreciable difference in LE.
H
ereditary non-polyposis colorectal cancer (HNPCC) is
an autosomal dominant disorder predisposing to
cancer. It has been estimated that 2–5% of all cases
of colorectal cancer (CRC) are due to HNPCC.1–3 Identification
of the DNA mismatch repair (MMR) genes responsible for
the disease has facilitated diagnosis of HNPCC and made it
possible to identify carriers of the mutated gene within a
family. These carriers have a high risk of developing CRC,
endometrial cancer, and other cancers associated with
HNPCC. One of the hallmarks of the syndrome is the
occurrence of multiple tumours in an individual. These
include multiple primary CRCs or the combined occurrence
of CRCs, endometrial cancer, and other related cancers.4 5
The risk of developing a metachronous CRC was estimated
to be 20–30% within 10 years after treatment of the first
CRC.6 This forms the basis for the recommendation to
perform colectomy with an ileorectal anastomosis (that is,
subtotal colectomy) in patients with CRC due to an MMR
gene defect.
Recently, a number of studies on the effectiveness of
periodic examination of the colorectum have been pub-
lished.7 8 Ja¨rvinen et al reported that surveillance led to a 56%
reduction in the CRC rate in a group of screened mutation
carriers compared with a group of carriers that did not
undergo surveillance examinations.7 A recent study on 114
Dutch families showed that regular colonoscopic surveillance
leads to the identification of mainly local tumours.9
Subtotal colectomy performed for CRC leads to a sig-
nificant reduction in quality of life (QOL) compared with the
general population.10 The SCOTIA group prospectively com-
pared the difference in QOL after subtotal colectomy and
segmental resection in sporadic CRC. They concluded that
segmental resection was associated with fewer bowel
function problems and therefore was the preferred treatment
in left sided malignant colonic obstruction.11
In view of the above findings the question rises whether
subtotal colectomy remains the preferred treatment in
HNPCC patients with a primary CRC. The main goal of this
study was to compare the potential health effects in terms of
life expectancy (LE) between patients that underwent
subtotal colectomy followed by surveillance of the rectum,
and those that underwent a more conservative surgical
procedure (that is, segmental resection or hemicolectomy)
followed by surveillance of the remaining bowel.
METHODS
Markov model
A Markov model was constructed using DATA 3.5 (TreeAge
Software, Inc., Williamstown, Massachusetts, USA) to
compare different treatment strategies for CRC in HNPCC
patients. In brief, a model was constructed comprising the
possible health states of a patient (patient with a Dukes’ A, B,
or C tumour). Subsequently, all relevant possible health
transitions were recognised. The likelihood of transferring
from the original health state to the next over time is
reflected by transition probabilities—that is, the chance of
transition from one state to another state (for example,
patients may develop a second tumour after surgery for their
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first CRC). The state to state transition was characterised by a
probability distribution (based on the chance of developing a
second CRC derived from literature study). The model follows
a hypothetical cohort of mutation carriers over time and
tracks the annual incidence of CRC by stage and mortality.
Short term mortality associated with surgery was also
incorporated.
Remaining LE was calculated after three different types of
surgical approaches for CRC: (1) proctocolectomy with
ileoanal anastomosis that was assumed to eliminate all risk
of CRC and the need for postoperative surveillance; (2)
subtotal colectomy with ileorectal anastomosis followed by
surveillance of the rectum; and (3) partial colectomy—that is,
segmental resection or hemicolectomy followed by surveil-
lance of the remaining bowel. Surveillance was defined as
colonoscopy every two years after segmental resection or
hemicolectomy and flexible sigmoidoscopy of the remaining
rectal segment every two years after subtotal colectomy.
Primary model outcome was the LE. In addition, we
differentiated between survivals with various parts of the
colon intact. Remaining LE values for a mutation carrier were
calculated after the three different types of surgical proce-
dures at the age of CRC detection of 27 years, 47 years, and 67
years.
Data sources and assumptions
The probabilities and pertaining sources used in the Markov
model are listed in table 1.
Risks of a metachronous CRC after surgery
(1) Proctocolectomy was assumed to eliminate all risk of
CRC.
(2) The risk of rectal cancer after subtotal colectomy varies
across studies and ranges from 3.4% to 10% every 10 years.9 12
On the basis of the most recent study, the risk of rectal cancer
after subtotal colectomy was assumed to be 4% after 10 years.
(3) The risk of a metachronous tumour after partial
colectomy varies from 15% to 30%.6 9 On the basis of our
own recent data, we estimated the risk of CRC after
segmental resection at 16% after 10 years.
Colorectal cancer stages
Information on the stages of CRCs when detected by
surveillance was derived from two large scale studies from
the Netherlands and Finland. The distribution of the stages
detected (2 year after a negative surveillance examination
while on the Dutch or Finnish surveillance program were
used, as shown in table 1 (Dukes’ A 32%, Dukes’ B 54%, and
Dukes’ C 14%).
Survival and mortality
Information on colorectal carcinoma survival was derived
from recent studies on survival in HNPCC patients.13 14 Five
year survival rates were assumed to be 98% in the case of
Dukes’ A, 80% for Dukes’ B, and 60% for Dukes’ C.13 We
assumed a preoperative mortality rate of 0.5%.15–18
RESULTS
If cancer is detected while on the surveillance program,
proctocolectomy with ileoanal anastomosis will lead to the
greatest LE of 34.8 years for a mutation carrier at age 27
years. Subtotal colectomy with ileorectal anastomosis leads to
an LE of 33.9 years whereas segmental resection or
hemicolectomy leads to an LE of 31.6 years. The benefit of
subtotal colectomy compared with segmental resection or
hemicolectomy decreases as CRC is detected at an older age.
The LE gain of subtotal colectomy compared with segmental
resection or hemicolectomy is 2.3 years at age 27 years, one
year at age 47 years, and 0.3 years at age 67 years.
If the first CRC detected while on the screening program is
a Dukes’ stage A carcinoma, proctocolectomy with ileoanal
anastomosis will lead to the greatest LE of 47.1 years for a
mutation carrier at age 27 years. Subtotal colectomy with
ileorectal anastomosis leads to an LE of 45.8 years whereas
segmental resection or hemicolectomy leads to an LE of 42.4
years. The LE gain of subtotal colectomy compared with
segmental resection or hemicolectomy is 3.4 years at age 27
years, 1.5 years at age 47 years, and 0.4 year at age 67 years.
Note however that this survival is conditional on the tumour
being Dukes’ stage A. Information on exact stage is not
available prior to operation and therefore the survival benefit
cannot be considered representative. In table 2, the LE values
of all possible surgical options are shown for different Dukes’
stages.
DISCUSSION
Since the identification of the genes responsible for HNPCC,
clinicians are more aware of this condition and, consequently
an increasing number of families are recognised. An
important question is whether the clinical management of
CRC, associated with HNPCC, should differ from that of
sporadic CRC. Until now, there was general agreement that
subtotal colectomy was the preferred surgical treatment for a
patient from a well defined HNPCC family with an early CRC.
The rationale for this recommendation is the significant risk
of developing a subsequent metachronous CRC, reported by
several research groups.6 9 However, a recent study showed
that periodic colonoscopic examinations of family members
at high risk for HNPCC led to a significant reduction in the
CRC rate.7 The vast majority of tumours, detected by
surveillance, were in an early stage. Another recent study
showed that subtotal colectomy in patients with familial
adenomatous polyposis led to a significant reduction in QOL
compared with the general population.10 With respect to this
observation, it should be realised that QOL may be better
after subtotal colectomy in HNPCC patients than in patients
with familial adenomatous polyposis because in the latter
group usually only the rectum (10–15 cm) is preserved.
Based on the results of these recent studies, we wondered
whether subtotal colectomy is still the treatment of first
choice. To address this problem we performed a decision
analysis study and compared the health effects between the
main surgical options. Of note however was the fact that the
cancer risks used in our model were drawn from retrospective
studies and therefore possible bias may have occurred. At a
time when a decision should be made on the best surgical
approach, the exact pathological staging of the tumour is
unknown. Intensive surveillance has been shown to lead to
the detection of mainly local tumours (that is, Dukes’ A and
Table 1 Probabilities and sources of the Markov model
Variable Value (%) Ref
10 year risk of a metachronous CRC after:
Proctocolectomy 0
Subtotal colectomy with ileorectal anastomosis 4 9 12
Segmental resection or hemicolectomy 16 9
Distribution of screen detected CRC stages
(2 year
7–9
Dukes’ A 32
Dukes’ B 54
Dukes’ C 14
Colorectal cancer 5 year survival rates 13
Dukes’ A 98
Dukes’ B 80
Dukes’ C 60
Mortality rate associated with colorectal surgery 0.5 14–18
CRC, colorectal cancer.
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B) and therefore this is the most likely to expect. However,
Dukes’ stage C tumours are still detected in a small
proportion of subjects while on the program. Therefore, we
made the calculations in our model both for a cohort of
patients with a distribution of colorectal tumours as actually
encountered in surveillance programs as well as for a cohort
of patients that would enter the model with a Dukes’ A
tumour. The results of our study showed that in young
patients, subtotal colectomy and protocolectomy lead to a
significant increase in LE compared with segmental resection
or hemicolectomy. The earlier the stage at which cancer was
detected and the younger the patient at diagnosis, the greater
was the benefit of subtotal colectomy and proctocolectomy.
Besides LE, the risk of a secondary surgery weighs in the
decision on surgical treatment. Assuming a constant risk of
16% every 10 years after partial colectomy, patients that
develop a primary CRC below the age of 60 years have a 20–
60% risk of secondary surgery for a new CRC whereas the risk
of rectal cancer after subtotal colectomy is approximately four
times lower. On the basis of our findings and these latter
considerations, we consider subtotal colectomy as the
preferred treatment in young patients at high risk of
HNPCC. Although proctocolectomy was associated with the
largest increase in LE, we do not consider this option in
HNPCC patients because of the worse functional results after
this type of surgery compared with the results reported after
subtotal colectomy.19 However, if the primary cancer lies in
the rectum, conventional hemicolectomy or subtotal colec-
tomy do not apply. In these cases proctocolectomy with an
ileoanal anastomosis appears to be the treatment of first
choice.
In older patients (for example, .60 years) proctocolectomy
and subtotal colectomy lead to only a slight increase in LE,
even if the tumour is detected in the most favourable stage
(that is, Dukes’ stage A). Also, in older patients, the lifetime
risk of developing a second CRC is relatively low. As a
consequence, in these patients we consider segmental
resection as an appropriate surgical option. In general,
subtotal colectomy should be avoided in a patient with a
history of poor sphincter function. When choosing partial
colectomy, it is very important to rule out the occurrence of a
synchronous tumour. Unfortunately, studies on QOL after
different surgical treatments do not specifically consider
HNPCC patients.11 For these patients, the risk of a synchro-
nous or metachronous tumour after a limited resection might
have a considerable impact on QOL due to fear of cancer. This
argument may also be used in decision making.
For detection of CRC in patients with a suspected family
history of HNPCC, immunohistochemical expression analysis
of MMR proteins and/or microsatellite instability analysis on
biopsies taken at colonoscopic examinations are useful tools
to confirm the presence of microsatellite instability. In view
of the above results, it may be of interest to a patient to use
these molecular genetic tools before deciding on surgical
treatment.
In conclusion, although intensive surveillance of HNPCC
patients reduces the incidence of CRC and overall mortality,
there remains a substantial risk of developing (mainly early)
CRC while on a program. If CRC is detected while on a
program, in young patients (,60 years) subtotal colectomy
seems to be the treatment of choice in view of the difference
in life expectancy between the two options and the possible
decrease in cancer fear as the risk of secondary cancer
decreases. In older patients, segmental resection is also an
appropriate option and should be discussed with the patient.
Large prospective clinical studies should be considered to
confirm our findings. Also, future studies should address
how the fear of a second cancer after limited surgery
influences quality of life.
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Table 2 Life expectancy of patients with colon cancer depending on treatment offered
and age at first detection
Life expectancy from first detection onwards
Age 27 y Age 47 y Age 67 y
Hemicolectomy overall* 31.6 20.6 10.5
Subtotal colectomy overall 33.9 21.6 10.8
Proctocolectomy overall 34.8 21.9 10.8
Hemicolectomy Dukes’ A 42.4 27.4 13.7
Subtotal colectomy Dukes’ A 45.8 28.9 14.1
Proctocolectomy Dukes’ A 47.1 29.4 14.2
Hemicolectomy Dukes’ B 29.1 19.0 9.8
Subtotal colectomy Dukes’ B 31.1 19.8 10.0
Proctocolectomy Dukes’ B 31.8 20.1 10.0
Hemicolectomy Dukes’ C 16.9 11.3 6.2
Subtotal colectomy Dukes’ C 17.6 11.6 6.2
Proctocolectomy Dukes’ C 18.0 11.7 6.2
*Overall takes into account a distribution of Dukes’ stages A, B, and C of 32%, 54%, and 14%, respectively.
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